XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Note 7 - Intangible Assets | 6 Months Ended
--- | ---
Dec. 31, 2023
Notes to Financial Statements |
Intangible Assets Disclosure [Text Block] | Note 7 - Intangible Assets The following table provides the summary of the Company’s intangible assets as of December 31, 2023 and June 30, 2023, respectively. Carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period.
|  | December 31, 2023 |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Weighted- |
|  |  |  |  |  |  |  |  |  | Net |  |  | Average |
|  | Carrying |  |  | Accumulated |  |  | Carrying |  |  | Remaining |
|  | Amount |  |  | Amortization |  |  | Amount |  |  | Life (in years) |
|  | (in thousands) |
Definite-lived intangibles: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired product technology rights |  | $ | 41,467 |  |  | $ | (11,777 | ) |  | $ | 29,690 |  |  |  | 11.04 |
Acquired technology right |  |  | 30,200 |  |  |  | (4,943 | ) |  |  | 25,257 |  |  |  | 14.25 |
Acquired product distribution rights |  |  | 6,207 |  |  |  | (5,443 | ) |  |  | 764 |  |  |  | 0.50 |
Total intangible assets |  | $ | 77,874 |  |  | $ | (22,163 | ) |  | $ | 55,711 |  |  |  | 12.35 |
|  | June 30, 2023 |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Weighted- |
|  |  |  |  |  |  |  |  |  | Net |  |  | Average |
|  | Carrying |  |  | Accumulated |  |  | Carrying |  |  | Remaining |
|  | Amount |  |  | Amortization |  |  | Amount |  |  | Life (in years) |
|  | (in thousands) |
Definite-lived intangibles: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired product technology rights |  | $ | 42,176 |  |  | $ | (10,881 | ) |  | $ | 31,295 |  |  |  | 11.49 |
Acquired technology right |  |  | 30,200 |  |  |  | (4,054 | ) |  |  | 26,146 |  |  |  | 14.75 |
Acquired product distribution rights |  |  | 6,207 |  |  |  | (4,678 | ) |  |  | 1,529 |  |  |  | 1.00 |
Total intangible assets |  | $ | 78,583 |  |  | $ | (19,613 | ) |  | $ | 58,970 |  |  |  | 12.67 |
The following table summarizes the estimated future amortization expense to be recognized over the next five fiscal years and periods thereafter:
|  | December 31, |
|  | (in thousands) |
2024 (remaining 6 months) |  | $ | 3,259 |
2025 |  |  | 4,989 |
2026 |  |  | 4,989 |
2027 |  |  | 4,989 |
2028 |  |  | 4,988 |
Thereafter |  |  | 32,497 |
Total future amortization expense |  | $ | 55,711 |
Acquired Product Technology Rights The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. Karbinal ER. The Company acquired and assumed all rights and obligations pursuant to the Supply and Distribution Agreement, as Amended, with Tris Pharma, Inc. (“Tris”) for the exclusive rights to commercialize Karbinal ER in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in August of 2033, with an optional additional 20-year extension. Poly-Vi-Flor and Tri-Vi-Flor. The Company acquired and assumed all rights and obligations pursuant to a Supply and License Agreement and various assignment and release agreements, including a previously agreed to Settlement and License Agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States. ADHD Portfolio. As part of the Neos Acquisition, the Company acquired product technology for the production and sale of Adzenys XR-ODT and Cotempla XR-ODT. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 17 years. Acquired Technology Right TRRP Technology. As part of the Neos Acquisition, the Company acquired Time Release Resin Particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlies the ADHD portfolio and can potentially be used in future product development initiatives as well. Acquired Product Distribution Rights (and customer list) In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. During the fourth quarter of fiscal 2023, the acquired product distribution rights incurred an impairment charge of $3.0 million due to the discontinuation of products in the Consumer Health Segment. Acquired In-Process R&D IPR&D – NT0502. As part of the Neos Acquisition, the Company acquired in-process research and development associated with NT0502, a new chemical entity being developed for the treatment of sialorrhea, which is excessive salivation or drooling. As this is an indefinite-lived intangible asset, this acquired asset remains an indefinite-lived asset until the completion or abandonment of the associated research and development efforts. If a product using this technology is eventually approved for commercial sale, at that time, the IPR&D will begin amortizing on a straight-line basis over the life of the product. During fiscal 2023, the Company terminated its development program of NT0502. As a result, the Company fully impaired the IPR&D of NT0502, recording impairment expense of $2.6 million to its Rx Segment during the three months ended December 31, 2022. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.6 million and $1.5 million for the three months ended December 31, 2023 and 2022, respectively, and $3.3 million and $3.0 million for the six months ended December 31, 2023 and 2022, respectively.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration